AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|
27.9 C
New York
Tuesday, September 1, 2026

Tag: group

newssourceFORcompanyinformationcontent1releasesmarket

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

Changan Group Unveils Its In-house Developed ADAS — SDA Pilot

CHONGQING, China, June 14, 2026 /PRNewswire/ -- At the 28th Chongqing International Auto Exhibition, Changan Group showcased its full brand lineup including CHANGAN NEVO,...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

BABCOCK & WILCOX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important June 15 Deadline in...

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

NASDAQ: WGS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against GeneDx Holdings Corp. (WGS)

Did you buy WGS securities between April 16, 2025, and May 4, 2026?

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...

AESC and Prevalon Energy Sign 10+ GWh Strategic Supply Agreement to Support Global Energy Storage Growth

SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...

Hozpitality Celebrates Hospitality Excellence at the Middle East Chef Excellence Awards, F&B Excellence Awards and Leaders Powerlist 2026

DUBAI, UAE, June 13, 2026 /PRNewswire/ -- Hozpitality Group successfully hosted the 9th Middle East Chef Excellence Awards 2026 alongside the 4th Middle East...

Hozpitality Celebrates Hospitality Excellence at the Middle East Chef Excellence Awards, F&B Excellence Awards and Leaders Powerlist 2026

DUBAI, UAE, June 13, 2026 /PRNewswire/ -- Hozpitality Group successfully hosted the 9th Middle East Chef Excellence Awards 2026 alongside the 4th Middle East...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGroup

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers